Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
Clinical trial NCT05437510 · COMPLETED
Trial details
- NCT number
- NCT05437510
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-08
- Primary completion
- 2024-03-27
- Enrollment
- 8057
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.